PULSE BIOSCIENCES, INC.

8-K · plse20260607c_8k.htm iXBRL

0001625101

 2026-06-11
 2026-06-11

  

 UNITED STATES

 SECURITIES AND EXCHANGE COMMISSION

 Washington, D.C. 20549

  

 FORM 8-K

  

 CURRENT REPORT

 Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

  

 Date of Report (Date of Earliest Event Reported): June 11, 2026

  

 Pulse Biosciences, Inc.

 (Exact Name of Registrant as Specified in Its Charter)

  
  
  

 Delaware

 001-37744

 46-5696597

 (State or Other Jurisdiction

 of Incorporation)

 (Commission

 File Number)

 (IRS Employer

 Identification No.)

  

 3957 Point Eden Way  

 Hayward , California   94545

 (Address of Principal Executive Offices) (Zip Code)

  

 510 - 906-4600

 (Registrant’s Telephone Number, Including Area Code)

  

 Not Applicable

 (Former Name or Former Address, If Changed Since Last Report)

  

 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see  General Instruction A.2. below):

  

 ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

  

 ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

  

 ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  

 ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

 Securities registered pursuant to Section 12(b) of the Act:

  

 Title of Each Class

 Trading Symbol(s)

 Name of Each Exchange on Which Registered

 Common stock , $0.001 par value per share

 PLSE

 The Nasdaq Stock Market

 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

  

 Emerging growth company ☐

  

 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

  

  

  

  

 Item 5.07

 SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS .

  

 On June 11, 2026, Pulse Biosciences, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The Annual Meeting was a virtual meeting held via live audio webcast. The stockholders of the Company voted on the following items at the Annual Meeting:

  

  

 1.

 to elect seven directors to hold office until the Company’s 2027 annual meeting and until their successors are duly elected and qualified, subject to earlier resignation or removal;

  

  

 2.

 to ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026;

  

 The voting results for each of these proposals are detailed below:

  

  

 1.

 Election of Directors

  

 Nominee

  

 For

  

 Against

  

 Abstained

  

 Broker Non-votes

 Robert W. Duggan

  
 33,443,582
  

 1,583,174

  

 388

  

 10,974,550

 Paul A. LaViolette

  
 34,264,295
  

 759,401

  

 3,448

  

 10,974,550

 Maria Sainz
  
 35,007,101
  
 18,349
  
 1,694
  
 10,974,550

 Manmeet S. Soni

  
 33,560,875
  

 1,464,574

  

 1,695

  

 10,974,550

 Darrin R. Uecker

  
 34,246,413
  

 779,036

  

 1,695

  

 10,974,550

 Richard A. van den Broek

  
 34,278,978
  

 746,471

  

 1,695

  

 10,974,550

 Mahkam Zanganeh, D.D.S.

  
 34,241,938
  

 783,511

  

 1,695

  

 10,974,550

  

 Each director nominee was duly elected to serve until the 2027 Annual Meeting and until his or her successor is duly elected and qualified.

  

  

 2.

 Ratification of Appointment of Independent Registered Public Accounting Firm

  

 For

  

 Against

  

 Abstained

  

 Broker Non-votes

 45,976,355

  

 8,265

  

 17,074

  

 N/A

  

 The stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

  

  

  

  

 SIGNATURE

  

 Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  

  

 PULSE BIOSCIENCES, INC.

  

  
  
  

  
  
  

 Date: June 11, 2026

 By:

 /s/ Jon Skinner

  

  
  

 Jon Skinner

  

  
  

 Chief Financial Officer

 (Principal Financial Officer)